| Drug General Information |
| Drug ID |
D05GMV
|
| Former ID |
DPR000108
|
| Drug Name |
SMP-534
|
| Drug Type |
Small molecular drug
|
| Indication |
Diabetic nephropathy [ICD9: 250.4; ICD10:E11.21]
|
Preclinical |
[1]
|
|---|
| Company |
Dainippon Sumitomo Pharma
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C11H14O2S
|
| Canonical SMILES |
CC1=C(SC(C1=O)(C)C=C(C)C=C)O
|
| InChI |
1S/C11H14O2S/c1-5-7(2)6-11(4)9(12)8(3)10(13)14-11/h5-6,13H,1H2,2-4H3/b7-6+/t11-/m1/s1
|
| InChIKey |
HGCGJTZCWZFGBT-XUIVZRPNSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
13347, 621341, 819775, 7890788, 12015257, 16288707, 17405466, 24278631, 32964498, 36888281, 46391893, 46491024, 46505720, 48169378, 50054156, 50106765, 50106766, 52110779, 53778014, 53813060, 57391946, 57404693, 84975004, 92304107, 103551068, 104065270, 104634710, 121361562, 124750089, 134338703, 134339547, 134340616, 135030651, 137245183, 140421192, 160967345, 163564862, 164187185, 179678465, 184534105, 208013918, 237212483, 238329620, 241163324
|
| Target and Pathway |
| Target(s) |
MAP kinase p38 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Rap1 signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Oocyte meiosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
VEGF signaling pathway
|
|
Osteoclast differentiation
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Platelet activation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
T cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Neurotrophin signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Dopaminergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
GnRH signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Prolactin signaling pathway
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis C
|
|
Influenza A
|
|
Epstein-Barr virus infection
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
B cell activation
|
|
EGF receptor signaling pathway
|
|
FGF signaling pathway
|
|
Interferon-gamma signaling pathway
|
|
Oxidative stress response
|
|
Parkinson disease
|
|
TGF-beta signaling pathway
|
|
Ras Pathway
|
|
p53 pathway feedback loops 2
|
|
p38 MAPK pathway
|
|
Pathway Interaction Database
|
RhoA signaling pathway
|
|
Signaling mediated by p38-gamma and p38-delta
|
|
Reactome
|
NOD1/2 Signaling Pathway
|
|
p38MAPK events
|
|
Activation of PPARGC1A (PGC-1alpha) by phosphorylation
|
|
CDO in myogenesis
|
|
DSCAM interactions
|
|
VEGFA-VEGFR2 Pathway
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Insulin Signaling
|
|
MAPK Cascade
|
|
MAPK Signaling Pathway
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Signal Transduction of S1P Receptor
|
|
Parkinsons Disease Pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
NGF signalling via TRKA from the plasma membrane
|
|
Myogenesis
|
|
Integrin-mediated Cell Adhesion
|
|
DSCAM interactions
|
|
Regulation of toll-like receptor signaling pathway
|
| References |
| REF 1 | Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63. |
|---|
